Miller KD et al. |
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. |
2014 |
J. Clin. Oncol. |
pmid:24733796
|
Giordano SH et al. |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. |
2014 |
J. Clin. Oncol. |
pmid:24799465
|
Galsky MD et al. |
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. |
2008 |
J. Clin. Oncol. |
pmid:18362364
|
Dzimitrowicz H et al. |
T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. |
2016 |
J. Clin. Oncol. |
pmid:27298406
|
Diéras V et al. |
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. |
2014 |
J. Clin. Oncol. |
pmid:25024070
|
Younes A et al. |
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. |
2012 |
J. Clin. Oncol. |
pmid:22753910
|
Krop IE et al. |
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. |
2012 |
J. Clin. Oncol. |
pmid:22649126
|
Sandra K et al. |
Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine. |
2016 |
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. |
pmid:27160547
|
Fan Y et al. |
Effects of modulation of pentose-phosphate pathway on biosynthesis of ansamitocins in Actinosynnema pretiosum. |
2016 |
J. Biotechnol. |
pmid:27173582
|
Fan Y et al. |
Process optimization with alternative carbon sources and modulation of secondary metabolism for enhanced ansamitocin P-3 production in Actinosynnema pretiosum. |
2014 |
J. Biotechnol. |
pmid:25456055
|
Floss HG |
Combinatorial biosynthesis--potential and problems. |
2006 |
J. Biotechnol. |
pmid:16414140
|
Lin CM and Hamel E |
Effects of inhibitors of tubulin polymerization on GTP hydrolysis. |
1981 |
J. Biol. Chem. |
pmid:6114958
|
Roach MC and Ludueña RF |
Different effects of tubulin ligands on the intrachain cross-linking of beta 1-tubulin. |
1984 |
J. Biol. Chem. |
pmid:6480599
|
Bai RL et al. |
Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. |
1990 |
J. Biol. Chem. |
pmid:2211617
|
Bai RL et al. |
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. |
1991 |
J. Biol. Chem. |
pmid:1874739
|
Hatano K et al. |
Biosynthetic origin of aminobenzenoid nucleus (C7N-unit) of ansamitocin, a group of novel maytansinoid antibiotics. |
1982 |
J. Antibiot. |
pmid:7174527
|
Tanida S et al. |
Ansamitocin analogs from a mutant strain of Nocardia. I. Isolation of the mutant, fermentation and antimicrobial properties. |
1981 |
J. Antibiot. |
pmid:7275830
|
Izawa M et al. |
Ansamitocin analogs from a mutant strain of Nocardia. II. Isolation and structure. |
1981 |
J. Antibiot. |
pmid:7275831
|
Tanida S et al. |
Ansamitocins, maytansinoid antitumor antibiotics. Producing organism, fermentation, and antimicrobial activities. |
1980 |
J. Antibiot. |
pmid:7380728
|
Nakahama K et al. |
Microbial conversion of ansamitocin. |
1981 |
J. Antibiot. |
pmid:7333971
|
Izawa M et al. |
Demethylation of ansamitocins and related compounds. |
1981 |
J. Antibiot. |
pmid:7333972
|
Izawa M et al. |
Hydroxylation of ansamitocin P-3. |
1981 |
J. Antibiot. |
pmid:7333973
|
Lu C et al. |
A novel amide N-glycoside of ansamitocins from Actinosynnema pretiosum. |
2004 |
J. Antibiot. |
pmid:15303496
|
Carroll BJ et al. |
Identification of a set of genes involved in the formation of the substrate for the incorporation of the unusual "glycolate" chain extension unit in ansamitocin biosynthesis. |
2002 |
J. Am. Chem. Soc. |
pmid:11960423
|
Moss SJ et al. |
Identification of asm19 as an acyltransferase attaching the biologically essential ester side chain of ansamitocins using N-desmethyl-4,5-desepoxymaytansinol, not maytansinol, as its substrate. |
2002 |
J. Am. Chem. Soc. |
pmid:12047169
|
Taft F et al. |
Timing of the Delta(10,12)-Delta(11,13) double bond migration during ansamitocin biosynthesis in Actinosynnema pretiosum. |
2009 |
J. Am. Chem. Soc. |
pmid:19292483
|
Spiteller P et al. |
The post-polyketide synthase modification steps in the biosynthesis of the antitumor agent ansamitocin by Actinosynnema pretiosum. |
2003 |
J. Am. Chem. Soc. |
pmid:14624546
|
Wenzel SC et al. |
On the biosynthetic origin of methoxymalonyl-acyl carrier protein, the substrate for incorporation of "glycolate" units into ansamitocin and soraphen A. |
2006 |
J. Am. Chem. Soc. |
pmid:17076505
|
Wang HH et al. |
Tau overexpression inhibits cell apoptosis with the mechanisms involving multiple viability-related factors. |
2010 |
J. Alzheimers Dis. |
pmid:20413892
|
Weiler D et al. |
Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer. |
2015 |
J Thorac Oncol |
pmid:25789838
|
Chuang JC et al. |
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. |
2017 |
J Thorac Oncol |
pmid:28167203
|
Yao Y et al. |
Preparative isolation and purification of anti-tumor agent ansamitocin P-3 from fermentation broth of Actinosynnema pretiosum using high-performance counter-current chromatography. |
2010 |
J Sep Sci |
pmid:20235129
|
Gibiansky L and Gibiansky E |
Target-mediated drug disposition model and its approximations for antibody-drug conjugates. |
2014 |
J Pharmacokinet Pharmacodyn |
pmid:24322877
|
Haddish-Berhane N et al. |
On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. |
2013 |
J Pharmacokinet Pharmacodyn |
pmid:23933716
|
Jumbe NL et al. |
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. |
2010 |
J Pharmacokinet Pharmacodyn |
pmid:20424896
|
Suchocki JA and Sneden AT |
Characterization of decomposition products of maytansine. |
1987 |
J Pharm Sci |
pmid:11002812
|
Wiggins B et al. |
Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates. |
2015 |
J Pharm Sci |
pmid:25631158
|
Lu SX et al. |
Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. |
2005 |
J Pharm Sci |
pmid:15729708
|
Mohamed HE et al. |
Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol. |
2018 |
J Pharm Biomed Anal |
pmid:29258046
|
Liu Y et al. |
LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1). |
2017 |
J Pharm Biomed Anal |
pmid:28131055
|
Iwamoto N et al. |
LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients. |
2017 |
J Pharm Biomed Anal |
pmid:28648785
|
Heudi O et al. |
Quantitative analysis of maytansinoid (DM1) in human serum by on-line solid phase extraction coupled with liquid chromatography tandem mass spectrometry - Method validation and its application to clinical samples. |
2016 |
J Pharm Biomed Anal |
pmid:26771131
|
Liu Z et al. |
An API LC/MS/MS quantitation method for ansamitocin P-3 (AP3) and its preclinical pharmacokinetics. |
2004 |
J Pharm Biomed Anal |
pmid:15533675
|
Shafaee MN et al. |
Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. |
2017 |
J Oncol Pract |
pmid:28678590
|
Baron JM et al. |
Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. |
2015 |
J Oncol Pharm Pract |
pmid:24682654
|
Parikh A et al. |
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. |
2017 |
J Natl Compr Canc Netw |
pmid:28040715
|
Liu Z et al. |
Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. |
2005 |
J Mass Spectrom |
pmid:15674857
|
Schönfeld K et al. |
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. |
2017 |
J Hematol Oncol |
pmid:28077160
|
Sibaud V et al. |
T-DM1 extravasation: first description. |
2016 |
J Eur Acad Dermatol Venereol |
pmid:25879278
|
Zhong P et al. |
αβ Integrin-targeted reduction-sensitive micellar mertansine prodrug: Superb drug loading, enhanced stability, and effective inhibition of melanoma growth in vivo. |
2017 |
J Control Release |
pmid:27986551
|